Regeneron Phase 3 in first-line unresectable or metastatic melanoma misses primary endpoint
Regeneron Phase 3 fianlimab plus cemiplimab trial in first-line unresectable or metastatic melanoma misses primary endpoint of progression-free survival vs pembrolizumab
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.